Navigation Links
GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
Date:8/7/2013

LONDON, Aug. 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on Wednesday, 14 August, 2013 at 2:00 p.m. ET. The conference will be held at the InterContinential Boston in Boston, MA.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section at www.gwpharm.com.

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in th
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
2. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
3. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
4. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. HealthEconomics.Com Launches a New Specialty Pharma Newsletter to Worldwide Community of Industry Insiders Within Specialty Pharmaceuticals
7. Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
8. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
9. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
10. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
11. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The AMA is pleased to share with ... that Alaska Governor Sean Parnell has signed House Bill ... use of Unmanned Aircraft Systems and the continuation of ... that it is, “An Act relating to unmanned aircraft ... aircraft system.” It defines State of Alaska laws regarding ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: AVAN ) ... developed for the treatment of Glioblastoma,Multiforme (GBM), will ... the 44th,Annual Meeting of the American Society of ... at McCormick Place in Chicago from May 30 ...
... Digirad Corporation,(Nasdaq: DRAD ), a leading provider ... offices, hospitals and imaging centers, today,announced the signing ... School of Medicine in Baltimore, Md., Under ... available to read,diagnostic images for primary care physicians, ...
... Partners released our,2008 studies of executive compensation in the ... ( http://www.dolmatconnell.com ),today and issued the below press release ... some very interesting findings, summarized in the press,release, that ... If,you would like to discuss any of the findings ...
Cached Biology Technology:AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 2Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 4DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance 2DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance 3
(Date:8/22/2014)... the bees. But that old expression leaves out ... process for flowering plants is particularly complex and ... reproductive cells. New research from an international team ... Carnegie,s Wolf Frommer, David Ehrhardt, and Guido Grossmann ... guides flowering plant fertilization. It is published in ...
(Date:8/21/2014)... Ind. -- A new study of American singles ... men have the highest orgasm rates. On average, ... with their sexual orientation making little difference. For ... average, women experience orgasm 62.9 percent of the ... and this pattern varies with women,s sexual orientation, ...
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Viruses take down massive algal blooms, with big implications for climate 2
... researchers have discovered how malaria parasites persuade red blood cells ... parasites. The malaria marauders hack into the red cell's signaling ... spring open the door to the cell. But researchers have ... signal to prevent the parasite from breaking in. ...
... human mothers are probably happy that they typically have one, ... low birth numbers combined with competition often spelled extinction. , ... hard for them to respond to rapid perturbations in the ... department head at Penn State. "Through time we see ...
... very small. , Nano small. , A Michigan State ... polymer films from buckling and wrinkling. It's a new solution ... in new technology such as electronic monitors. , ... seems crossed with science fiction ?from microdermabrasians to lasers ...
Cached Biology News:Researchers discover surprising drug that blocks malaria 2Birth rate, competition are major players in hominid extinctions 2Birth rate, competition are major players in hominid extinctions 3Nanotechnology shows promise as next wrinkle fighter 2
... A high quality source of ... the enzymatic digestion of casein. It ... fermentations and has been used in ... casein, pancreatic digest For microbiology pH6.8 ...
... Human Raji cells were cultured in RPMI 1640 ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... mini incubation trays are disposable ... screen antigens that have been ... tray has eight 10.5 cm ... accommodate strips cut from blotted ...
Biology Products: